WHO REGIONAL OFFICE FOR AFRICA COVID-19 RAPID POLICY BRIEF SERIES

SERIES 1: COVID-19 CASE MANAGEMENT - TREATMENT OPTIONS

NUMBER 001-02: Efficacy of Corticosteroids in Patients with COVID-19 pneumonia

Based on information as at 12 June 2020
Number 001-02: Efficacy of Corticosteroids in Patients with COVID-19 pneumonia

WHO/AF/ARD/DAK/15/2020

© WHO Regional Office for Africa 2020

Some rights reserved. This work is available under the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 IGO licence (CC BY-NC-SA 3.0 IGO; https://creativecommons.org/licenses/by-nc-sa/3.0/igo).

Under the terms of this licence, you may copy, redistribute and adapt the work for non-commercial purposes, provided the work is appropriately cited, as indicated below. In any use of this work, there should be no suggestion that WHO endorses any specific organization, products or services. The use of the WHO logo is not permitted. If you adapt the work, then you must license your work under the same or equivalent Creative Commons licence. If you create a translation of this work, you should add the following disclaimer along with the suggested citation: “This translation was not created by the World Health Organization (WHO). WHO is not responsible for the content or accuracy of this translation. The original English edition shall be the binding and authentic edition”.

Any mediation relating to disputes arising under the licence shall be conducted in accordance with the mediation rules of the World Intellectual Property Organization.


Cataloguing-in-Publication (CIP) data. CIP data are available at http://apps.who.int/iris.

Sales, rights and licensing. To purchase WHO publications, see http://apps.who.int/bookorders. To submit requests for commercial use and queries on rights and licensing, see http://www.who.int/about/licensing.

Third-party materials. If you wish to reuse material from this work that is attributed to a third party, such as tables, figures or images, it is your responsibility to determine whether permission is needed for that reuse and to obtain permission from the copyright holder. The risk of claims resulting from infringement of any third-party-owned component in the work rests solely with the user.

General disclaimers. The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of WHO concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted and dashed lines on maps represent approximate border lines for which there may not yet be full agreement.

The mention of specific companies or of certain manufacturers’ products does not imply that they are endorsed or recommended by WHO in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters.

All reasonable precautions have been taken by WHO to verify the information contained in this publication. However, the published material is being distributed without warranty of any kind, either expressed or implied. The responsibility for the interpretation and use of the material lies with the reader. In no event shall WHO be liable for damages arising from its use.

Designed and printed in the WHO Regional Office for Africa, Brazzaville, Congo
BACKGROUND

There is a growing need to provide COVID-19 evidence, acknowledging the needs of the policy/decision-makers. This rapid policy brief aims to summarize relevant research, in a timely manner and thereby facilitating their use in decision making.

The outbreak of the new coronavirus infections COVID-19 become quickly a pandemic and global health emergency. Currently there is no specific anti-viral therapies, and its management is mainly supportive [1], even though several ongoing studies are now under investigation for the treatment of this life-threatening disease and some of them began to show strong findings.

The increasing knowledge about the pathophysiology of SARS-CoV-2 infection is leading to consider some steroids drugs as potential treatment options for the management of COVID-19. In this document we will critically summarized the evidences on either positive or negative effect of steroids commonly used to treat other diseases in this particular situation of COVID-19.

Death rate among COVID-19 patients is high in patients with risk factors including obesity, older age (>65 years), the male sex, high blood pressure, stroke, coronary heart disease, heart failure, poorly controlled diabetes, chronic obstructive respiratory illnesses, renal chronic disease, and cancer among the key drivers of COVID-19 deaths [2]. Patients with severe COVID-19 pneumonia had markedly increased inflammatory markers such as CRP, IL-6 and FER, which signified occurrence of the inflammatory reaction phase. Meanwhile, most patients developed fever, cough, dyspnea and markedly decline in oxygen saturation, which are the early clinical manifestations of ARDS. This is the indicator for corticosteroid admission to treat these patients [3]. Physicians are concerned whether steroids used in treatment of chronic diseases such as rheumatoid arthritis and asthma affected outcomes of COVID-19 [4]. Sixteen studies have examined the effectiveness of treating COVID-19 patients with anti-inflammatory drugs especially corticosteroids.

SEARCH STRATEGY / RESEARCH METHODS

The research consisted in using four databases: PUBMED, WHO COVID-19, IRIS (WHO Institutional Repository for Information Sharing) and Google Scholar to pull out papers published from 1 December to 12 June 2020 for relevant studies on (COVID-19 or SARS or MERS or coronavirus) and “corticosteroids”. Randomized controlled clinical trials available for analysis, case–control, cohort studies and case series were eligible for inclusion provided data were available.

First inventory was to explore papers on the subject and scoped Africa related evidences. With this search strategy, 106 titles and abstracts of studies were found. All of them were conducted out of Africa.

Sixteen publications were retained according to criteria of consistency to assess the efficacy of corticosteroid treatment of patients with coronavirus disease 2019 (COVID-19) that was objective for this rapid policy brief.
Dexamethasone is first drug shown to save lives, in the RECOVERY (Randomized Evaluation of COVid-19 thErapY) a randomized clinical trial to test a range of potential treatments for COVID-19, the effect of dexamethasone was most striking among critically ill patients on ventilators. Dexamethasone reduced deaths by one-third in ventilated patients (rate ratio 0.65 [95% confidence interval 0.48 to 0.88]; p=0.0003) and by one fifth in other patients receiving oxygen only (0.80 [0.67 to 0.96]; p=0.0021). There was no benefit among those patients who did not require respiratory support (1.22 [0.86 to 1.75]; p=0.14) [5]. There is currently paucity of evidence on effectiveness of ICS in treatment of COVID-19 patients [6]. In all analyzed studies, systemic steroid treatment has not been recommended for COVID-19. Three reported cases of the COVID-19 pneumonia successfully treated with ciclesonide inhalation. Rationale of the treatment is to mitigate the local inflammation with inhaled steroid that stays in the lung and to inhibit proliferation of the virus by antiviral activity. Larger and further studies are warranted to confirm the result of these cases [7]. Conventional therapeutics for asthma, including inhaled corticosteroids, allergen immunotherapy (AIT), and anti-IgE monoclonal antibody, might also reduce the risks of asthmatics suffering infection of the virus through alleviating inflammation or enhancing antiviral defense. Research indicate that in patients with severe COVID-19 pneumonia, early, low-dose and short-term application of corticosteroid was associated with a faster improvement of clinical symptoms and absorption of lung focus [8,9,10]. In people with COVID-19, corticosteroids may theoretically modulate the inflammatory response and reduce the risk of developing ARDS [11]. From a systematic review quality assessment, there is currently very low-quality evidence from a case series report from Japan of improvement in three patients with COVID-19 requiring oxygen, but not ventilatory support, after being given inhaled ciclesonide [12].

### SUMMARY OF AFRICA-SPECIFIC LITERATURE ON THE SUBJECT

Not found

### POLICY FINDINGS

- Critically ill patients on ventilators and those who receive oxygen therapy but not on ventilators, these can receive dexamethasone at a low or moderate dose of six milligrams per day (either by mouth or by intravenous injection) for ten days [5].
- Corticosteroids may reduce mortality for patients with COVID-19 and ARDS. For patients with severe COVID-19 but without ARDS, evidence regarding benefit from different bodies of evidence is inconsistent and of very low quality [13].
- During inflammatory reaction phase, most patients developed early clinical manifestations of ARDS and markedly decline in oxygen saturation. Corticosteroid admission is indicated to treat these patients and Early application of low-dose corticosteroid could improve the treatment effect, presenting as improvement of hypoxia and fever symptom, shorten the disease course, and accelerating focus absorption. Benefited from condition monitoring and refined management, no serious complications caused by corticosteroid happened in these patients. The corticosteroid formulation used in a cohort study was methylprednisolone, a median effect corticosteroid with a half-life of 12-36, which has been proved to be associated with a better intensity of immunosuppression [14]. The dosage, duration and route of methylprednisolone administration can be 1-2mg/kg/d for 5-7 days via intravenous injection. Nevertheless, the specific dosage and duration for individual patient must be determined on the clinical manifestations, leucocyte and lymphocyte count, inflammatory index and lesion range [8].
The Chinese Thoracic Society has issued the following expert consensus on the use of corticosteroids in CoV-2 SARS pneumonia [15,16]:

- The benefits and risks must be carefully weighed before using corticoids;
- Corticosteroids should be used with caution in critically ill patients with CoV-2 SARS pneumonia;
- In patients with hypoxemia caused by underlying disease or who regularly use corticosteroids for chronic diseases, the use of extra steroids should be used with caution;
- Dosage should be low to moderate (equivalent to ≤ 0.5-1 mg/kg/day of methylprednisolone) and the duration should be short (≤ 7 days).

In the current pandemic situation, corticosteroid therapy is not recommended for bacterial Ears, Nasal and Throat infections.

In rhinology, there is no indication for systemic corticosteroid therapy in the current COVID-19 situation, especially in cases of nasosinusal polyposis or infectious or very painful sinusitis. However, patients are advised to continue with their usual local corticosteroid therapy as a nasal spray or by inhalation. Treatments with corticosteroid nasal sprays can still be prescribed if there is no other therapeutic alternative. However, treatment with corticosteroid aerosols should be avoided due to the risk of spreading the virus to people around the patient.

In Grade V and VI Bell’s palsy according to the House-Brackmann grading system, a week’s course of oral corticosteroids is recommended. Corticosteroid therapy is also recommended in cases of sudden hearing loss of more than 60 dB, either in the form of intratympanic injections or a week’s course of oral medication. Finally, systemic or local corticosteroid therapy is not indicated for bacterial Ears, Nasal and Throat infections. [4]

Pneumonia in confirmed COVID-19 positives this treatment can be indicated

- A: Ciclesonide (Alvesco) 200 μg Inhaler (56 puffs/kit), 2 times a day, 2 inhalations each time
- B: Ciclesonide (Alvesco) 200 μg Inhaler (56 puffs/kit), 3 times a day, 2 inhalations each time

Take A as a basis, consider changing to B for severe cases and cases where the effect is not sufficient. Considering that the drug must reach the infected area, “deep inhalation” is the most reasonable method of administration at present [16].

10 ONGOING RESEARCH IN THE AFRICAN REGION
Not found

11 AFRO RECOMMENDATIONS FOR FURTHER RESEARCH

WHO/AFRO invites all researchers to scientifically document the corticosteroid efficacy in patients with COVID-19 Pneumonia; Also interactions between COVID-19 and lung chronic disease such as asthma deserve further attention and clarification in the African Region.

WHO/AFRO encourages sharing scientifically research and knowledge related to the use of corticosteroids in patients with COVID-19 pneumonia.
REFERENCES


7. Shuang Liu, Yuxiang Zhi & Sun Ying. COVID-19 and Asthma: Reflection During the Pandemic.


### Title:

Efficacy of Corticosteroids in patients with COVID-19 pneumonia

---

**Based on Evidence for COVID-19, Other Coronavirus Infections, Influenza, Community-Acquired Pneumonia and Acute Respiratory Distress Syndrome: A Systematic Review and Meta-Analysis.**


---

**BRIEF PRODUCED BY:** Jean Claude Nshimirimana, Humphrey Karamagi, Kwami Dadji, Benson Droti, Regina Titi-Ofei, Aminata B. Seydi, Pascal Mouhouelo, Julie Nabyonga, Akpaka Kalu, Hillary Kipruto, James Asamani and Felicitas Zawaira